Literature DB >> 27504169

The Results of Autologous Skin Test in Patients with Chronic Urticaria in Hamadan, Iran.

Mojgan Safari1, Hooshyar Sayemiri2.   

Abstract

INTRODUCTION: The etiology of chronic urticaria is unknown in many cases. In this study, we demonstrated the presence of autoimmune antibodies in patients with chronic urticaria by using of the Autologous Serum Skin Test (ASST).
METHODS: We performed a cross-sectional study to detect the presence of autologous antibodies in the serum of 38 patients (25 females and 13 males) with idiopathic chronic urticaria who were referred to the Hamedan Allergy Clinic in 2014. All of the necessary tests for demonstrating chronic urticaria were performed, including complete blood count (CBC), thyroid and liver functionality tests, and the prick test but they did not confirm the cause of chronic urticaria. We conducted the Autologous Serum Skin Test on the patients and analyzed the results.
RESULTS: In 15 patients (39%), the ASST was positive. Of the 15 patients with positive autoimmune chronic urticaria, five patients (33%) were males, and 10 patients (67%) were females.
CONCLUSION: We concluded that many patients with chronic urticaria have autoimmune urticaria. It is the reason for the lack of the response to treatment with common medications for urticaria. New ways of treatment must be considered for them.

Entities:  

Keywords:  Autologous serum skin test; Chronic; Urticaria

Year:  2016        PMID: 27504169      PMCID: PMC4965204          DOI: 10.19082/2539

Source DB:  PubMed          Journal:  Electron Physician        ISSN: 2008-5842


1. Introduction

Urticaria affects 15 to 30% of the general population, and approximately 0.5 to 1% of the cases are chronic. Chronic urticaria is a common and disturbing disease characterized by short-lived weals that occur daily or almost daily for at least six weeks with no identifiable cause in 70 to 80% of patients (1). The pathogenesis of chronic idiopathic urticaria is not entirely clear. In 1986, Grattan et al. reported that the intra-dermal injection of a serum factor led to the creation of weals in chronic urticarial patients (i.e., Autologous Serum Skin Test, ASST) (2). In 1993, Hide et al. suggested an autoimmune etiology for chronic idiopathic urticaria (3). At least one-third of patients with idiopathic chronic urticaria, ranging from 25 to 60%, have circulating functional autoantibodies against the high-affinity IgE receptor Fc_RI, or less commonly, IgE (4). In clinical practice, a positive ASST is used as a method to determine the existence of auto-antibodies to FcɛRI and is assumed to express the presence of an autoimmune pathogenesis of urticaria (5, 6). The ASST is a reliable in vivo test; it is performed by injecting the patient’s own serum into the skin, since it is able to reveal the chronic idiopathic urticaria auto reactivity (7). During the active phase of the disease, a weal and flare reaction may develop (8, 9). There is a correlation between a positive Autologous Serum Skin Test (ASST) and the presence of anti-FcɛRI and anti-IgE auto-antibodies (10). False positive results due to the formation of other vasoactive mediators while the serum is being processed and false negative results due to degradation of histamine-releasing factors may be induced (7). Although the basophil histamine release assay is the best standard for detecting auto-antibodies in chronic urticaria, it has its own difficultly because of the need for fresh basophiles from the patient (1). Therefore, the ASST test is the only functional and cost-effective method for the diagnosis of autoimmune chronic urticaria. Our study was focused on evaluating the prevalence of positive ASST’s in patients with chronic urticaria in the Hamedan geographical region.

2. Material and methods

This study consisted of patients who were referred to the Allergy Clinic with the chief complaint of hives for more than six weeks. Complete blood count (CBC) and erythrocyte sedimentation rate (ESR) tests, liver and thyroid functionality tests, and urine analysis (U/A), urine culture (U/C), stool examination (S/E) and skin allergens reviews were conducted, and all were normal. Patients were assumed not to have any exclusion criteria that could void the study, such as the existence of any other systemic disease in the previous reviews; any obvious causes for the hives; history of insect bites; recent usage of a drug; or vaccine and physical urticaria. We explained to the patients how the test was going to be performed as well as its probable implications and future trends in tests and treatment. We also imposed an obligation of not using drugs (antihistamines) for at least 48 hours before the test. Only if the patient agreed with the terms and conditions were the tests conducted. In the first stage, 5 cm3 of the patient’s blood were sampled in a no heparin cast pipe and allowed to clot at room temperature. The patient’s serum was centrifuged at 2000 rpm for 15 minutes. Next, 0.05 cm3 of autologous serum was injected intradermally into the forearm, followed by the injection of the same amount of saline-as a control-in the opposite side. The results were read after 30 minutes. Indurations of more than 1.5 mm in diameter than that of the saline control were considered as positive results (11).

3. Results

In this study, 38 patients participated, 25 (66%) females and 13 (34%) males. The ASST was performed for all 38 patients. The ASST was positive in 15 patients (39%) and negative in 23 patients (61%). Out of 15 patients with autoimmune chronic urticaria, five patients (33%) were males and 10 (67%) were females. Out of 23 patients with non-autoimmune chronic urticaria, 15 patients (65%) were females and eight (35%) were males. The ages of the patients who participated in the study were between 7 and 60. The ages of patients were between 1–10, 11–20, 21–30, 31–40, 41–50, and 51–60 in 1, 3, 13, 8, 9, and 4 patients, respectively. Their mean age was 34. Most of the patients were between the ages of 21 and 30, and this group also had the highest number of positive test results. Due to the low number of the samples in the different age groups, the chi-squared test was not used. The percentage of positive results of the ASST in this study among the patients with chronic urticaria was 39%.

4. Discussion

In our study, most of the chronic urticaria occurred in women, however, more research is required before we can generalize this finding. The major difficulties in the process of treating the patients with chronic urticaria were as follows. The treatments often were time consuming and energy wasting, which caused the quality of life of many of the patients to become downgraded drastically. This may persist for a long time. Moreover, the patients made demands of the doctors in various ways. They often sought a variety of drugs in addition to intolerable regimes, which were difficult and demanding. Considering the significant frequency of the occurrence of autoimmune urticaria among the patients with chronic urticaria, the ASST as a primary screening test is favorable, and it is easy to perform. In this study, 38 patients with chronic urticaria were screened. Twenty-five of them were females, and 13 were males. The difference in gender does not imply more frequent chronic urticaria in females. This may be due to the sensitivity among women or the higher number of female patients referred to the clinic and who participated in the test. Although we could not ignore the female dominance in the presentation of urticarial, especially the chronic form, it could be a clue for other researchers to prove this theory. In 10 out of 25 females (40%) with chronic urticaria, the ASST test was positive. Also, in five out of 13 males (38%), the ASST test was positive. Therefore, there was no correlation between the ASST results and the patient’s gender. In the study of Emma Guttman on 32 patients with chronic urticaria, the ASST test was positive in 53% of the patients (8). Taskapan studied the results of the ASST test in patients with chronic urticaria in 2008 and mentioned that 52.5% had positive results. Taskapan found that patients with chronic urticaria have auto-antibodies with high affinity to FcɛRIα receptors, which leads to the release of histamine (12). Godse mentioned that the ASST is the only practical and available test for the diagnosis of autoimmune urticaria, with 70% sensitivity and 80% specificity. He studied 45 patients with chronic urticaria and reported the ASST as positive in 12 (26%) cases, with the male to female ratio of 1 to 2 (13). In a study of 100 patients in 2008, Mametha (1) reported the ASST test as positive in 34% of the cases. Autologous serum skin tests were positive in 63.5% and 24% in patients with chronic urticaria in the studies of Colgecen et al. (14) and Lunge et al. (15), respectively. As mentioned before, our study consisted of 38 patients, and the ASST test was determined to be positive in 15 (39%) cases. In other words, 39% had autoimmune urticaria, and 61% had non-autoimmune urticaria. This conforms to the results of other researchers.

5. Conclusions

The adjustment or modification of the medication and food regimes has an important role in reducing the problems the patients are struggling with. It is essential to do more research to confirm whether the immunosuppressive drugs are effective enough to be the actual treatment for chronic autoimmune urticaria. We concluded that many patients with chronic urticaria have autoimmune urticaria. This is the reason for the lack of the response to treatment with common medications for urticaria. New ways of treatment must be considered for them.
  15 in total

1.  The autologous serum skin test in a cohort of chronic idiopathic urticaria patients compared to respiratory allergy patients and healthy individuals.

Authors:  Emma Guttman-Yassky; Reuven Bergman; Carcom Maor; Merav Mamorsky; Shimon Pollack; Eduardo Shahar
Journal:  J Eur Acad Dermatol Venereol       Date:  2007-01       Impact factor: 6.166

2.  Is puncture skin test adequate to detect autoreactivity in patients with chronic urticaria?

Authors:  R Asero; A Tedeschi
Journal:  Clin Exp Dermatol       Date:  2008-07-04       Impact factor: 3.470

3.  Evaluation of etiological factors in patients with chronic urticaria.

Authors:  Emine Colgecen; Kemal Ozyurt; Ali Irfan Gul; Serap Utas
Journal:  Acta Dermatovenerol Croat       Date:  2015       Impact factor: 1.256

4.  Serum IgG autoantibodies directed against the alpha chain of Fc epsilon RI: a selective marker and pathogenetic factor for a distinct subset of chronic urticaria patients?

Authors:  E Fiebiger; D Maurer; H Holub; B Reininger; G Hartmann; M Woisetschläger; J P Kinet; G Stingl
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

Review 5.  Pathophysiology of chronic urticaria.

Authors:  Malcolm W Greaves
Journal:  Int Arch Allergy Immunol       Date:  2002-01       Impact factor: 2.749

6.  The autologous serum skin test in the follow-up of patients with chronic urticaria.

Authors:  A Fusari; C Colangelo; F Bonifazi; L Antonicelli
Journal:  Allergy       Date:  2005-02       Impact factor: 13.146

7.  Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria.

Authors:  M Hide; D M Francis; C E Grattan; J Hakimi; J P Kochan; M W Greaves
Journal:  N Engl J Med       Date:  1993-06-03       Impact factor: 91.245

8.  Assessment of histamine-releasing activity of sera from patients with chronic urticaria showing positive autologous skin test on human basophils and mast cells.

Authors:  R Asero; M Lorini; S U Chong; T Zuberbier; A Tedeschi
Journal:  Clin Exp Allergy       Date:  2004-07       Impact factor: 5.018

9.  Clinical and laboratory parameters in predicting chronic urticaria duration: a prospective study of 139 patients.

Authors:  E Toubi; A Kessel; N Avshovich; E Bamberger; E Sabo; D Nusem; J Panasoff
Journal:  Allergy       Date:  2004-08       Impact factor: 13.146

10.  Correlation of serum antithyroid microsomal antibody and autologous serum skin test in patients with chronic idiopathic urticaria.

Authors:  Snehal Balvant Lunge; Milind Borkar; Sushil Pande
Journal:  Indian Dermatol Online J       Date:  2015 Jul-Aug
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.